![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
All Oral Fixed-Dose Combination Ledipasvir/Sofosbuvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Experienced Genotype 1 HCV-Infected Patients: The Phase 3 ION-2 Study
|
|
|
Reported by Jules Levin E
EASL 2014 April 9-13 London, UK
Nezam Afdhal1, Rajender K. Reddy2, Paul Pockros3, Adrian M. Di Bisceglie4, Sanjeev Arora5, Jenny C. Yang6, Hadas Dvory-Sobol6, Yanni Zhu6, Phil S. Pang6, William T. Symonds6, John G. McHutchison6, Mark Sukowski7, Paul Kwo8
1Beth Israel Deaconess Medical Center, Boston, MA, USA; 2University of Pennsylvania, Philadelphia, PA, USA; 3Scripps Clinic, La Jolla, CA; 4St Louis University, Saint Louis, MO, USA; 5University of New Mexico, Albuquerque, NM; 6Gilead Sciences, Inc., Foster City, CA; 7Johns Hopkins Medical Center, Baltimore, MD, USA; 8Indiana University School of Medicine, Indianapolis, IN, USA
![EASL1.gif](../images/041414/041414-8/EASL1.gif)
![EASL2.gif](../images/041414/041414-8/EASL2.gif)
![EASL3.gif](../images/041414/041414-8/EASL3.gif)
![EASL4.gif](../images/041414/041414-8/EASL4.gif)
![EASL5.gif](../images/041414/041414-8/EASL5.gif)
![EASL6.gif](../images/041414/041414-8/EASL6.gif)
![EASL7.gif](../images/041414/041414-8/EASL7.gif)
![EASL8.gif](../images/041414/041414-8/EASL8.gif)
![EASL9.gif](../images/041414/041414-8/EASL9.gif)
![EASL10.gif](../images/041414/041414-8/EASL10.gif)
![EASL11.gif](../images/041414/041414-8/EASL11.gif)
![EASL12.gif](../images/041414/041414-8/EASL12.gif)
![EASL13.gif](../images/041414/041414-8/EASL13.gif)
![EASL14.gif](../images/041414/041414-8/EASL14.gif)
![EASL15.gif](../images/041414/041414-8/EASL15.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|